EMA401
Total Payments
$133,160
Transactions
15
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1,700 | 3 | 0 |
| 2018 | $47,750 | 11 | 0 |
| 2017 | $83,710 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $133,160 | 15 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $83,710 | 0 |
| A DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED DOSE RANGING TRIAL TO DETERMINE THE SAFETY AND EFFICACY OF THREE DOSE LEVELS OF EMA401 IN REDUCING 24 HOUR AVERAGE PAIN INTENSITY SCORE IN PATIENTS WITH POST HERPETIC NEURALGIA EMPHENE | Novartis Pharmaceuticals Corporation | $49,450 | 0 |
Top Doctors Receiving Payments for EMA401
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $133,160 | 15 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $133,160
Product Information
- Type Drug
- Total Payments $133,160
- Total Doctors 0
- Transactions 15
About EMA401
EMA401 is a drug associated with $133,160 in payments to 0 healthcare providers, recorded across 15 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2019. In 2019, $1,700 was paid across 3 transactions to 0 doctors.
The most common payment nature for EMA401 is "Unspecified" ($133,160, 100.0% of total).
EMA401 is associated with 2 research studies, including "OUTCOMES RESEARCH" ($83,710).